Overview

PET Biomarkers in Treatment Resistant Depression

Status:
Terminated

Trial end date:
2013-03-01

Target enrollment:

Participant gender:

Summary

The primary objectives of the study are to test whether brain Mono Amine Oxidase-A (MAO-A) levels are elevated in patients with treatment-resistant major depression, and to explore whether MAO-A brain levels predict treatment outcome with Mono Amine Oxidase Inhibitor (MAOI) medication in this population.

Phase:

Phase 4

Details

Lead Sponsor:

New York State Psychiatric Institute

Collaborator:

National Institute of Mental Health (NIMH)

Treatments:

Tranylcypromine